0.467

1.81% 0.008

Scienture Holdings Inc (SCNX)

Overview News Price History Discussions Forecast

Scienture Holdings Inc stock is traded at $0.467, with a volume of 788.29K. It is up +1.81% in the last 24 hours and up +12.87% over the past month. Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.

Previous Close:

$0.459

Open:

$0.4501

24h Volume:

788.29K

Relative Volume:

0.37

Market Cap:

$18.89M

Revenue:

$656.60K

Net Income/Loss:

$-16.79M

P/E Ratio:

-0.4347

EPS:

-1.0743

Net Cash Flow:

$-11.12M

1W Performance:

+12.74%

1M Performance:

+12.87%

6M Performance:

+16.82%

1Y Performance:

-61.38%

1-Day Range:

$0.4401

$0.4771

1-Week Range:

$0.3644

$0.4771

52-Week Range:

$0.2382

$2.60

Scienture Holdings Inc Stock (SCNX) Company Profile

Name

Scienture Holdings Inc

Sector

Healthcare (1089)

Industry

Pharmaceutical Retailers (7)

Phone

(800) 261 0281

Address

20 AUSTIN BLVD., COMMACK

Employee

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

SCNX's Discussions on Twitter

Compare SCNX vs HITI, PETS, POM, MEDS

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SCNX Scienture Holdings Inc	0.4601	18.85M	656.60K	-16.79M	-11.12M	-1.0743
HITI High Tide Inc	2.34	206.49M	486.49M	-33.29M	10.86M	-0.3627
PETS Petmed Express Inc	1.78	39.56M	179.02M	-57.29M	-33.01M	-2.7487
POM Pomdoctor Ltd Adr	0.8899	7.21M	0	0	0	0.00
MEDS Trxade Health Inc	1.525	4.21M	7.15M	4.03M	-11.33M	-5.40

Scienture Holdings Inc Stock (SCNX) Latest News

Aug 14, 2026

Scienture Holdings 2Q Loss/Shr 7c >SCNX - moomoo.com

Aug 14, 2026

Scienture Holdings Reports Q2 2026 Results, Launches REZENOPY™ and Narrows Losses - Quiver Quantitative

Aug 14, 2026

Scienture Holdings (SCNX) grows ARBLI revenue but remains loss-making in Q2 2026 - Stock Titan

Aug 13, 2026

Aug 12, 2026

SCIENTURE Launches REZENOPY as Second FDA-Approved Commercial Product - Yahoo Finance

Aug 12, 2026

Scienture launches naloxone nasal spray for opioid overdose By Investing.com - Investing.com Nigeria

Aug 12, 2026

Scienture launches naloxone nasal spray for opioid overdose - Investing.com

Aug 12, 2026

SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray - marketscreener.com

Aug 12, 2026

Scienture Holdings Announces Commercial Launch and Fulfillment of Initial Purchase Orders of Rezenopy Nasal Spray 10 Mg - marketscreener.com

Aug 12, 2026

EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US - Yahoo Finance

Aug 12, 2026

Aug 07, 2026

Scienture Holdings Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView

Aug 07, 2026